Somaform's New Interface Line Draws the Regulator's Eye

ZÜRICH — A regulator's letter is not a recall, but the market read it like one, and the augmentation world spent the week reading it more carefully still. Health authorities confirmed they have opened a safety review of Somaform Augmetics' newest neural-interface line — the high-bandwidth model that lets a user route more of their attention, and more of their nervous system, through the implant than any consumer product before it. The review is routine in form and pointed in substance: it asks whether the line crosses from augmentation into something the body was never meant to sustain. Somaform's founder, Julian Morrow, a longtime advocate for the augmented, called the scrutiny "the price of standing at the edge" and pledged full cooperation. The company insists the line is safe within its published limits. The regulators want to know what happens past them — how users behave when a device this capable is always on, always deeper, always offering one more channel of self. It is the oldest question in the field wearing new hardware: not whether enhancement is possible, but how much is too much, and who decides. The review will take months. The line stays on the market meanwhile. And a debate the industry hoped it had settled reopens, as it always does, at the frontier.